Immunology and Microbiology
T Cell
100%
Severe Acute Respiratory Syndrome Coronavirus 2
97%
COVID-19
87%
Immunoglobulin E
73%
Antineoplastic Activity
73%
Chimeric Antigen Receptor T-Cell
73%
Immunotherapy
73%
Tumor Antigen
73%
Virus
43%
Xenograft
29%
Cancer Immunotherapy
29%
Tumor Cell
29%
Monoclonal Antibody
29%
Type I Hypersensitivity
14%
Effector Cell
14%
Immune Dysregulation
14%
Viral Shedding
14%
Chimeric Antigen Receptor T-Cell Therapy
14%
Graft-Versus-Host Disease
14%
CRISPR/Cas9
14%
Renewable Energy
14%
Immunoglobulin E Antibody
14%
Immune System
14%
Cytotoxicity
14%
Cytokine Release Syndrome
14%
T Cell Receptor
14%
Interferon Gamma
14%
Cancer Cell
14%
Metabolite
14%
Bioinformatics
14%
Basophil Activation
14%
Medical Decision Making
14%
Vascularization
14%
Cell Surface
14%
Prevalence
14%
Overall Survival
14%
Humoral Immunity
14%
Interleukin 2
14%
Chimeric Antigen Receptor
14%
Intravenous Immunoglobulin
14%
Basophil
12%
Immunopathology
12%
Cell Composition
12%
Interleukin 10
12%
Interleukin 6
12%
Upregulation
12%
Chemokine
12%
Cytokine
12%
Plasmacytoid Dendritic Cell
12%
Medicine and Dentistry
T Cell
85%
COVID-19
73%
Glucose Transporter 5
73%
Antineoplastic Activity
73%
Cell Therapy
73%
Solid Malignant Neoplasm
43%
Severe Acute Respiratory Syndrome Coronavirus 2
24%
Diseases
24%
Fructose
14%
T Lymphocyte Receptor
14%
Tumor Microenvironment
14%
Vascularity
14%
Chimeric Antigen Receptor
14%
In Vitro
14%
Metabolite
14%
Clinical Trial
14%
Medical Decision Making
14%
Cancer
14%
Tumor Cell
14%
Cancer Immunotherapy
14%
Chemokine
12%
Immunopathology
12%
Cell Composition
12%
Interleukin 10
12%
Upregulation
12%
Disease Severity
12%
Interleukin 6
12%
Cytokine
12%
Plasmacytoid Dendritic Cell
12%
Basophil Cell
12%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
73%
Solid Malignant Neoplasm
73%
SARS Coronavirus
73%
Glucose Transporter 5
73%
Diseases
73%
Immunopathology
36%
Disease Severity
36%
Cytokine
36%
Chemokine
36%
Interleukin 6
36%
Interleukin 10
36%
Fructose
24%
Chimeric Antigen Receptor
24%
T Lymphocyte Receptor
24%
Malignant Neoplasm
24%
Tumor Microenvironment
24%
Clinical Trial
24%
Immunotherapy
24%